admin, Author at Invivoscribe

About admin

This author has not yet filled in any details.
So far admin has created 76 blog entries.

AACR Annual Meeting 2021

admin2021-02-27T01:27:29+00:00February 26th, 2021|Conferences|

April/May 2021 Week 1: April 10-15; Week 2: May [...]

EHS 3rd How to Diagnose and Treat Multiple Myeloma

admin2021-02-27T01:27:23+00:00February 26th, 2021|Conferences|

April 15-18, 2021 VIRTUAL CONFERENCE www.esh.org [...]

EAHP-SH 2021

admin2021-02-27T01:27:16+00:00February 26th, 2021|Conferences|

April 24-29, 2021 VIRTUAL CONFERENCE www.eahp-sh2021.com [...]

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

admin2021-02-22T20:29:22+00:00December 1st, 2020|2020 Videos, Videos, Webinars|

FEATURED PRESENTERS
Ola Landgren, PhD, MD / Swati Shah, MD

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

admin2021-02-11T19:51:54+00:00November 25th, 2020|2020 Publications, Publications|

VIEW PUBLICATION ⟶

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

admin2021-02-11T19:57:34+00:00November 22nd, 2020|2020 Publications, Publications|

VIEW PUBLICATION ⟶

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

admin2021-02-17T18:10:07+00:00November 17th, 2020|2020 Publications, Featured Publications, Publications|

VIEW PUBLICATION ⟶

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

admin2021-02-23T21:58:35+00:00November 16th, 2020|2020 Videos, AMP, Videos|

FEATURED PRESENTER
Dr. Bradley Patay

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

admin2021-02-23T01:19:53+00:00November 16th, 2020|2020 Videos, AMP, Videos|

FEATURED PRESENTERS
Yury Monczak, Ph.D / Ryan J. Schmidt, MD, PhD

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

admin2021-02-11T20:05:42+00:00October 30th, 2020|2020 Publications, Publications|

VIEW PUBLICATION ⟶

Load More Posts

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING

Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate
drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

About admin

AACR Annual Meeting 2021

EHS 3rd How to Diagnose and Treat Multiple Myeloma

EAHP-SH 2021

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

Browse our comprehensive menu of product & testing services.

A proven strategy to acceleratedrug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020 Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

About admin

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING

Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

A proven strategy to accelerate
drug approvals

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma